Financial Data and Key Metrics Changes - The company reported a 56% growth in revenue to AUD 804 million, marking its third consecutive year of double-digit revenue growth [15][17] - EBITDA improved by 25% to AUD 216 million, driven by strong demand for Illuccix and the launch of Gozellix [17][20] - The gross margin remained stable at 53%, with 94% of gross margin generated from the precision medicine business [19][20] Business Line Data and Key Metrics Changes - Revenue from the precision medicine business increased by 22% year-over-year, contributing an additional AUD 113 million [17][20] - The precision medicine business demonstrated a 28% increase in operating profit and a 25% increase in EBITDA [20] - The company invested AUD 157 million into product development, focusing on its late-stage pipeline [19] Market Data and Key Metrics Changes - The precision medicine portfolio delivered AUD 622 million in revenue, up 22% year-over-year, with sequential growth every quarter [28] - Illuccix is now available in 17 countries with reimbursement secured, and marketing authorizations exist in over 24 markets [32] - The company anticipates a 25% growth in precision medicine revenue in 2026, driven by the full year of RLS revenue [26] Company Strategy and Development Direction - The company aims to transition to a high-value therapeutic business, with planned R&D investment in the range of AUD 200 million to AUD 240 million for 2026 [24] - A dual product strategy for Illuccix and Gozellix is expected to enhance market share and manage economic needs of healthcare accounts [56] - The focus remains on reinvesting revenues back into the business rather than optimizing near-term earnings per share [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of double-digit revenue growth, with guidance set at AUD 950 million to AUD 970 million for 2026 [26][27] - The company is committed to disciplined financial management and anticipates strong momentum heading into 2026 [25][27] - Management highlighted the importance of clinical credibility and operational reliability in sustaining market leadership [30] Other Important Information - The company has over 30 sponsored and collaborative studies running, with four major trials identified as priorities for the year [46] - The ProstACT Global study is progressing well, with recruitment for part two ramping up [47] - The company is focused on expanding its product offerings and indications, particularly in key markets like China and Japan [32][33] Q&A Session Summary Question: When might data for 591 be available? - Management indicated that the company is not waiting on the FDA and will disclose data as soon as it is available [52][54] Question: Insights on the two-product strategy for Illuccix and Gozellix? - The two-product strategy allows the company to manage economic needs and adapt to changing reimbursement environments [56][59] Question: Will earnings be reinvested to achieve close to zero NPAT for F-26, F-27, and F-28? - Management confirmed that the majority of earnings will be reinvested back into the company for growth initiatives [66][67] Question: How much growth in precision medicine is coming from markets outside the US? - Currently, 95% of revenue is US-based, but the company expects this mix to change as it expands into other markets [72] Question: Thoughts on the collaboration with Atley and Stanford focusing on astatine-211? - Management expressed excitement about the potential of astatine-211 and its fit within the product portfolio [76]

Core Viewpoint - Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, alleging that the company engaged in bribery to encourage healthcare providers to prescribe its medications over alternatives [1]. Group 1: Allegations and Legal Actions - The lawsuit claims that Sanofi created programs that provided services to healthcare providers, which are alleged to constitute bribes in violation of the Texas Health Care Program Fraud Prevention Act [1]. - Attorney General Paxton is seeking over a million dollars in monetary relief, including civil penalties, and an injunction to prevent further unlawful acts by Sanofi [1]. - This is not the first legal action against Sanofi; the Attorney General has previously sued the company for failing to disclose the ineffectiveness of its blood clot prevention drug, Plavix, for certain patients [1]. Group 2: Context of Legal Environment - Last year, Texas also sued Eli Lilly for similar allegations of bribing providers to prescribe its most profitable drugs, including GLP-1 medications Mounjaro and Zepbound [1].

Core Viewpoint - Ocular Therapeutix Inc. shares declined following the announcement of Axpaxli treatment data for wet age-related macular degeneration, which did not meet investor expectations [1][2]. Group 1: Trial Results - The SOL-1 Phase 3 superiority trial showed that 74.1% of subjects treated with Axpaxli maintained vision at Week 36, compared to 65.9% in the aflibercept arm, resulting in a risk difference of 17.5% (p=0.0006) [4]. - At Week 52, 65.9% of subjects in the Axpaxli arm maintained vision, compared to 44.2% in the aflibercept arm, with a risk difference of 21.1% [6]. - The trial indicated that 80.6% of subjects in the Axpaxli arm were rescue-free at Week 24, significantly outperforming the aflibercept group [5]. Group 2: Commercial Outlook - The durability advantage of Axpaxli over the active control was smaller than anticipated, raising concerns about its commercial outlook in a market with established therapies [2]. - Ocular Therapeutix plans to submit a New Drug Application (NDA) based on the SOL-1 data, pending discussions with the U.S. FDA [8]. - If approved, Axpaxli could become the first tyrosine kinase inhibitor (TKI) commercialized for wet AMD, potentially holding a superiority label and best-in-disease durability [8]. Group 3: Acquisition Interest - Sanofi SA was reportedly bidding for Ocular Therapeutix, indicating potential interest in the company and its pipeline [7].

The S&P 500 (SNPINDEX:^GSPC) fell 0.28% to 6,861.89, breaking a three-day winning streak. Geopolitical tensions and weaker confidence weighed on the Nasdaq Composite (NASDAQINDEX:^IXIC), which slipped 0.31% to 22,682.73, and the Dow Jones Industrial Average (DJINDICES:^DJI), which dropped 0.54% to 49,395.16. Market movers Walmart (NASDAQ:WMT) fell after issuing weaker-than-expected guidance. This put pressure on Dow futures and retail peers. DoorDash (NASDAQ:DASH) and Medical Properties Trust (NYSE:MPT) ...

Financial Data and Key Metrics Changes - The company reported a significant year-over-year total revenue growth of 22%, with full-year 2025 revenues of $407.3 million, compared to $333.6 million in 2024 [30] - XPHOZAH revenues grew to $274.2 million, an increase of 73% compared to the full year of 2024 [31] - The net loss for 2025 was $61.6 million, or $0.26 per share, compared to a net loss of $39.1 million, or $0.17 per share, for 2024 [33] Business Line Data and Key Metrics Changes - IBSRELA achieved a remarkable revenue growth of 73% compared to 2024, with a 61% year-over-year growth in Q4 [5][11] - XPHOZAH saw total dispenses increase by 9% and paid dispenses by 41% when excluding Medicare compared to 2024 [18] - The IBS-C market grew by nearly 11% in 2025, with approximately 7 million prescriptions written [12] Market Data and Key Metrics Changes - The IBS-C market continues to grow double digits, indicating a robust demand for alternative treatments [12] - The company anticipates IBSRELA revenues for 2026 to be between $410 million and $430 million, representing at least 50% year-over-year growth [34] - XPHOZAH revenues are expected to be between $110 million and $120 million in 2026 [38] Company Strategy and Development Direction - The company aims to significantly grow IBSRELA and maintain XPHOZAH's momentum while advancing its pipeline of innovative medicines [9][41] - A new patent for IBSRELA and XPHOZAH was issued, expiring in 2042, which is part of the strategy to build a comprehensive intellectual property portfolio [6] - The company is focused on expanding its market presence through investments in prescriber engagement and patient education [16][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for IBSRELA, projecting it to reach $1 billion in revenue by 2029 [9] - The company is committed to patient access and has made bold decisions to ensure that all appropriate patients can access XPHOZAH [18] - Management highlighted the importance of disciplined cash management and execution, finishing 2025 in a stronger financial position than in 2024 [8] Other Important Information - The company has been cash flow positive for two consecutive quarters, with a total cash position of $264.7 million at the end of 2025 [34][40] - The company plans to invest approximately 25% more in operating expenses for 2026, focusing on R&D and commercial execution [39] Q&A Session Summary Question: Confidence in IBSRELA volume growth to meet guidance - Management expressed strong confidence in reaching the $430 million guidance, citing the vast patient population needing alternatives to current treatments [45][46] Question: Cadence of expenses and path to sustained cash flow positivity - Management indicated that while operating expenses will increase, they are growing at a slower rate than revenue, and they have been cash flow positive for the last two quarters [52][54] Question: Expectations for CIC trial dose levels - Management clarified that the lower doses in the CIC trial are part of a strategy to evaluate safety and efficacy, with a focus on finding the optimal dose [62][64] Question: Distinctions in the CIC market compared to other treatments - Management highlighted the need for different mechanisms of action in treating CIC, emphasizing the potential utility of tenapanor in this patient population [70][72] Question: Long-term growth for XPHOZAH post-2026 - Management noted that they do not benefit from Medicare base rate adjustments and are focused on ensuring patient access through Medicaid and commercial channels [87]

Full Year Results Presentation For personal use only February 20, 2026 ASX: TLX | NASDAQ: TLX - FY 2025 treatment 18 F -FET scan published in EJNMMI showing a patient with recurrent glioblastoma (GBM) who experienced a near -complete response following treatment with TLX101 -Tx (Iodofalan (¹³¹I), [¹³¹I]IPA), Telix's investigational LAT1 -targeted therapy. Patient representative scans, individual results may vary. Post - treatment Pre Presenters Agenda For personal use only Kyahn Williamson SVP Investor Rela ...

Financial Data and Key Metrics Changes - In 2025, Prothena reported a net cash used in operating and investing activities of $163.7 million, which was favorable compared to the guidance range of $170 million to $178 million [35] - The net loss for 2025 was $244.1 million, aligning with the guidance range of $240 million to $248 million [35] - As of December 31, 2025, Prothena had $308.4 million in cash, cash equivalents, and restricted cash, exceeding the guidance of $298 million [36] Business Line Data and Key Metrics Changes - Prothena's clinical pipeline saw significant advancements, with two partnered programs, prasinezumab and coramitug, moving into phase 3 clinical trials [5] - The phase 3 PARAISO trial for prasinezumab will evaluate 900 participants with early Parkinson's disease, while the CLEOPATTRA trial for coramitug will enroll approximately 1,280 patients with ATTR-CM [5][17] - The company anticipates potential milestone payments of up to $105 million in 2026 from these partnered programs [9][38] Market Data and Key Metrics Changes - The global market for Parkinson's disease treatment is significant, with over 10 million patients and no approved disease-modifying therapies currently available [13] - The ATTR-CM market represents a multi-billion dollar opportunity, with coramitug expected to capture substantial future milestone payments [18] Company Strategy and Development Direction - Prothena aims to capture value from its clinical partnerships and has a strategic priority to implement a share redemption program in 2026 [9][39] - The company is focused on advancing its preclinical portfolio and exploring research collaborations, particularly around its CYTOPE technology [9][39] - Prothena's strategic priorities are supported by a robust cash position, allowing for prudent capital utilization [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's execution and resilience in 2025, setting the stage for future growth [39] - The company is optimistic about the potential for significant medical advances in areas with high unmet needs, particularly in neurodegenerative diseases [42] - Management highlighted the importance of upcoming milestones and the potential for substantial clinical milestone payments in 2026 [46] Other Important Information - Prothena's collaborations with Bristol Myers Squibb progressed, with the phase 2 TargetTau-1 trial for BMS-986446 fully enrolled and expected to complete in the first half of 2027 [6] - The company introduced its CYTOPE technology, which aims to enable precise targeting of intracellular disease pathways [27] Q&A Session Summary Question: Key milestones for partnered program trials for PARAISO and CLEOPATTRA - Management outlined that significant activities are expected in 2026 and 2027, including updates on CYTOPE technology and data from the tau program with Bristol Myers Squibb [41][42] Question: Keeping the amyloid beta story alive versus competitors - Management discussed the advantages of the PRX012 transferrin-based approach, emphasizing its potential for robust amyloid removal and improved safety profile [50][52] Question: Data sharing from the phase one study of PRX019 - Management confirmed that data from the PRX019 study will be shared with Bristol Myers Squibb, who holds global rights to the program [61][66] Question: Data necessary for CYTOPE platform partnerships - Management highlighted the importance of demonstrating robust CNS activity and specificity in targeting TDP-43 aggregates to attract partnerships [69][73]

Group 1: Market Overview - The average forward price-to-earnings ratio (P/E) for the S&P 500 index is currently 21.5, significantly higher than the 10-year average of 17.6, indicating a challenging environment for finding bargains in the stock market [1] Group 2: Enterprise Products Partners - Enterprise Products Partners is a large midstream energy company with a diverse portfolio that includes pipelines, storage facilities, and deepwater docks [5] - The midstream segment of the energy sector is generally more stable than upstream and downstream segments due to long-term contracts and the facilitation of energy asset movement [6] - Enterprise has maintained consistent profitability with net margins over 10% and strong operating cash flow, allowing for substantial capital expenditures, projected between $2.5 billion and $2.9 billion this year [7] - Despite a recent increase in share price, Enterprise's stock remains relatively inexpensive with a forward P/E just above 13 and a dividend yield of nearly 5.9%, which is more than five times the average yield of S&P 500 components [8] Group 3: Bristol Myers Squibb - Bristol Myers Squibb is undergoing a business transformation as it shifts from reliance on blockbuster drugs like Revlimid and Eliquis, which are now part of its "legacy" portfolio, to a focus on its "growth" portfolio, particularly cancer treatment Opdivo [9][10] - The revenue from the growth portfolio increased by 16% year over year in the fourth quarter of 2025, indicating potential for future growth despite challenges from expiring patents on legacy drugs [10]

Core Insights - Johnson & Johnson announced promising results from the Phase 1b/2 OrigAMI-4 study, showing a 56% overall response rate for RYBREVANT FASPRO™ in first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) [1][2] - The study demonstrated a 10% complete response rate and a clinical benefit rate of 74%, indicating significant antitumor activity compared to current standards of care [1][2] - The combination of subcutaneous amivantamab and pembrolizumab targets key drivers of tumor growth and resistance, suggesting a potential shift in treatment paradigms for HNSCC [1][2] Study Results - In Cohort 2 of the OrigAMI-4 study, the confirmed overall response rate was 56% (22 out of 39 patients), with 6 complete responses and 18 partial responses [1] - At a median follow-up of 10.4 months, 46% of patients remained on treatment, and tumor shrinkage was observed in 82% of patients [1] - The median progression-free survival was reported at 7.7 months, with a median time to first response of 9.7 weeks [1] Safety Profile - The safety profile of RYBREVANT FASPRO™ combined with pembrolizumab was consistent with individual agents, with no new safety signals identified [1] - Common treatment-emergent adverse events included rash (49%), paronychia (46%), and hypoalbuminemia (41%), with 15% of patients experiencing administration-related reactions [1][2] - Treatment discontinuation due to adverse events occurred in four patients, indicating manageable safety concerns [1] Industry Context - HNSCC is an aggressive cancer type, with current standard treatments yielding low response rates (approximately 18% for PD-1 monotherapy) [1][2] - The introduction of RYBREVANT FASPRO™ represents a significant advancement in addressing unmet needs in HNSCC treatment, particularly for HPV-unrelated cases [1][2] - Ongoing studies, including the Phase 3 OrigAMI-5 study, will further evaluate the efficacy of RYBREVANT FASPRO™ in combination with carboplatin and pembrolizumab [1][2]

Core Viewpoint - Novo Nordisk is currently undervalued despite a significant decline in stock price and weak guidance for 2026, presenting a potential opportunity for contrarian dividend investors [1]. Group 1: Company Challenges - Novo Nordisk has faced challenges in the GLP-1 market, particularly due to inability to meet demand and competition from Eli Lilly's more effective drugs [2][5]. - The company has provided weak guidance for 2026, anticipating a decline in revenue and earnings, partly due to a drug pricing agreement with the U.S. government [5]. Group 2: Competitive Position - Novo Nordisk was the first to market a pill version of its GLP-1 drug, which may help regain market share before Eli Lilly's pill launch, as consumers generally prefer pills over injections [6]. - The company is developing an updated version of its GLP-1 drug to enhance competitiveness against Eli Lilly and is adopting a more aggressive stance against generic competitors [7]. Group 3: Financial Metrics - Novo Nordisk's price-to-earnings ratio stands at 13.5, significantly lower than Eli Lilly's 45, indicating a potentially attractive valuation [8]. - The company offers a dividend yield of 3.7%, with a payout ratio of approximately 40%, suggesting strong support for its dividend [8].